Oxadiazole inhibitors of leukotriene production

US8575201B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Alessandra Bartolozzi · Norwalk, US
• Todd Bosanac · New Milford, US
• Zhidong Chen · New Milford, US
• Stéphane De Lombaert · Madison, US
• Jonathon Alan Dines · Abingdon, GB
• John D. Huber · New York, US
• Weimin Liu · Sandy Hook, US
• Pui Leng Loke · Abingdon, GB
• Tina Morwick · New Milford, US
• Alan Olague · Shelton, US
• Doris Riether · Biberach an der Riß, DE
• Heather Tye · Abingdon, GB
• Lifen Wu · New Milford, US
• Renee M. Zindell · New Milford, US

Key dates

• Filing date: Sep 20, 2011
• Grant date: Nov 5, 2013
• Expiry date: Oct 3, 2031

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds of formula (I) and (IA):and pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.